Payment overview · 2025
General Payments
$1,502.45
86 reported records · 29 companies
Healthcare provider profile · identity verified
Stewart C. Greathouse, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LAKE CHARLES, LA · NPI 1740589621
Verified facts
What the public records show
CMS Open Payments records show Stewart C. Greathouse, M.D. received $1,502.45 in general payments during 2025 across 86 reported records.
ABBVIE INC. accounted for 18.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Trintellix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Eliquis by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $276.99 | 18.4% | 26 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $119.83 | 8.0% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $118.63 | 7.9% | 6 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $78.74 | 5.2% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $78.13 | 5.2% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $65.52 | 4.4% | 3 | 2025 |
| Noven Therapeutics, LLC | Unresolved — no canonical attribution shown | $60.91 | 4.0% | 3 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $55.97 | 3.7% | 3 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $46.73 | 3.1% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $45.37 | 3.0% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $44.44 | 3.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $44.28 | 3.0% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $40.52 | 2.7% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $39.44 | 2.6% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $39.11 | 2.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $38.94 | 2.6% | 2 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $36.82 | 2.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.17 | 2.3% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $33.17 | 2.2% | 1 | 2025 |
| INTUITIVE SURGICAL, INC. | Unresolved — no canonical attribution shown | $31.12 | 2.1% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $27.67 | 1.8% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $23.79 | 1.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.66 | 1.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.88 | 1.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.52 | 1.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.45 | 1.2% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $16.22 | 1.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.73 | 1.1% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $13.70 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,502.45 | 86 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $150.16 | 11 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $137.49 | 9 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $119.83 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $99.22 | 13 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $97.62 | 5 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $78.74 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $78.13 | 3 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $65.52 | 3 | 2025 |
Source payment records
|
|||||
| Xelstrym Normalized: xelstrym |
Drug | Noven Therapeutics, LLC | $60.91 | 3 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $55.97 | 3 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $46.73 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $45.37 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $44.44 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $40.52 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $39.44 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $39.11 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $37.13 | 2 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $36.82 | 2 | 2025 |
Source payment records
|
|||||
| FABRAZYME Normalized: fabrazyme |
Biological | GENZYME CORPORATION | $33.17 | 1 | 2025 |
Source payment records
|
|||||
| Da Vinci Surgical System Normalized: da vinci surgical system |
Device | INTUITIVE SURGICAL, INC. | $31.12 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $29.24 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.24 | 2 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $27.67 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $23.79 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $21.66 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $20.11 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.83 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.52 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $17.52 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $17.52 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.45 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.45 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.92 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.92 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $16.22 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.73 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.04 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $13.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 90 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 148 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
90 | 22 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
90 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
148 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
61 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 530 | 153 |
| Pantoprazole Sodium | Pantoprazole Sodium | 297 | 88 |
| Levothyroxine Sodium | Levothyroxine Sodium | 249 | 62 |
| Amlodipine Besylate | Amlodipine Besylate | 246 | 72 |
| Furosemide | Furosemide | 204 | 55 |
| Gabapentin | Gabapentin | 203 | 59 |
| Losartan Potassium | Losartan Potassium | 154 | 41 |
| Lisinopril | Lisinopril | 152 | 45 |
| Mounjaro | Tirzepatide | 148 | 21 |
| Alprazolam | Alprazolam | 136 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 135 | 37 |
| Metformin Hcl Er | Metformin Hcl | 130 | 36 |
| Omeprazole | Omeprazole | 124 | 35 |
| Tramadol Hcl | Tramadol Hcl | 123 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 114 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 112 | 31 |
| Potassium Chloride | Potassium Chloride | 105 | 28 |
| Clonazepam | Clonazepam | 102 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 101 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 95 | 25 |
| Valsartan | Valsartan | 95 | 29 |
| Montelukast Sodium | Montelukast Sodium | 92 | 24 |
| Trazodone Hcl | Trazodone Hcl | 91 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 90 | 28 |
| Jardiance | Empagliflozin | 90 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 87 | 18 |
| Meloxicam | Meloxicam | 86 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 86 | 32 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 73 | 24 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 73 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 71 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 71 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 68 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 67 | suppressed |
| Simvastatin | Simvastatin | 63 | 19 |
| Labetalol Hcl | Labetalol Hcl | 62 | 17 |
| Ozempic | Semaglutide | 61 | 12 |
| Allopurinol | Allopurinol | 58 | 15 |
| Glipizide | Glipizide | 57 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 56 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 54 | 43 |
| Prednisone | Prednisone | 54 | 41 |
| Amitriptyline Hcl | Amitriptyline Hcl | 53 | 18 |
| Sertraline Hcl | Sertraline Hcl | 53 | 17 |
| Bupropion Xl | Bupropion Hcl | 52 | 21 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 50 | 15 |
| Ipratropium Bromide | Ipratropium Bromide | 49 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 14 |
| Carvedilol | Carvedilol | 47 | 16 |
| Lorazepam | Lorazepam | 45 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 45 | 11 |
| Mirtazapine | Mirtazapine | 44 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | 13 |
| Pregabalin | Pregabalin | 43 | suppressed |
| Xarelto | Rivaroxaban | 43 | suppressed |
| Eliquis | Apixaban | 41 | suppressed |
| Metformin Hcl | Metformin Hcl | 41 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | 12 |
| Divalproex Sodium Er | Divalproex Sodium | 39 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 39 | 12 |
| Temazepam | Temazepam | 39 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 38 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 38 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 37 | suppressed |
| Famotidine | Famotidine | 37 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 35 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Estradiol | Estradiol | 33 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 32 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 32 | suppressed |
| Repatha Sureclick | Evolocumab | 32 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 31 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Linzess | Linaclotide | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Glimepiride | Glimepiride | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 12 |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Mupirocin | Mupirocin | 18 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Naproxen | Naproxen | 17 | 14 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 17 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Pentoxifylline | Pentoxifylline | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 13 |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Cefdinir | Cefdinir | 13 | 13 |
| Cephalexin | Cephalexin | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,502.45 · 86 records | ABBVIE INC. | ABRYSVO, AREXVY, Auvelity, Azstarys, BREZTRI, CAPLYTA, COMIRNATY, Cologuard Collection Kit, Da Vinci Surgical System, Dexcom G6 Transmitter, EVENITY, FABRAZYME, FANAPT, GEMTESA, IBSRELA, JARDIANCE, JATENZO, Jornay PM, Kerendia, LEQVIO, MOUNJARO, OTEZLA, PREVNAR 20, QULIPTA, Qelbree, REPATHA, REXULTI, SHINGRIX, TRINTELLIX, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XYOSTED, Xelstrym, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error